Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
A study published in npj Precision Oncology, a Nature journal, has highlighted the potential of advanced biomarker approaches to improve treatment selection in oncology, specifically evaluating treatment outcomes in metastatic breast cancer patients receiving trastuzumab deruxtecan. The peer-reviewed research featured Aditxt Inc.'s precision oncology subsidiary, Ignite Proteomics, and its Reverse Phase Protein Array platform.
The study found that quantitative HER2-related assays, including Ignite's platform, provided more predictive insight into patient outcomes than traditional immunohistochemistry methods in certain sub-cohorts. This suggests that pathway-level protein analytics could offer clinicians better tools for determining which patients are most likely to respond to specific cancer treatments.
Ignite Proteomics operates a CLIA-certified, CAP-accredited laboratory and delivers pathway-level protein analytics to guide precision oncology. The company's clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from limited biopsy material to support oncology research and clinical decision making. This capability allows for more detailed analysis of tumor biology than traditional methods, potentially leading to more personalized treatment approaches.
The research findings come as Aditxt continues to build its innovation platform focused on accelerating promising health innovations. The company currently operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women's health. The study's publication in a prestigious Nature journal adds credibility to the approach being developed by Ignite Proteomics and suggests growing scientific interest in advanced protein analysis for oncology applications.
For investors and researchers interested in following developments related to Aditxt, additional information is available through various financial news platforms. The broader implications of this research extend beyond the specific breast cancer treatment studied, potentially influencing how biomarkers are evaluated across multiple cancer types and treatment regimens. As precision medicine continues to evolve, platforms like Ignite's that can provide detailed protein pathway information from limited tissue samples may become increasingly important tools in the oncologist's arsenal.